WO2004024196A1 - Pansements destines au traitement des plaies infectees - Google Patents

Pansements destines au traitement des plaies infectees Download PDF

Info

Publication number
WO2004024196A1
WO2004024196A1 PCT/GB2003/003886 GB0303886W WO2004024196A1 WO 2004024196 A1 WO2004024196 A1 WO 2004024196A1 GB 0303886 W GB0303886 W GB 0303886W WO 2004024196 A1 WO2004024196 A1 WO 2004024196A1
Authority
WO
WIPO (PCT)
Prior art keywords
wound
wound dressing
barrier layer
layer
dressing according
Prior art date
Application number
PCT/GB2003/003886
Other languages
English (en)
Inventor
Paul Watt
Original Assignee
Johnson & Johnson Medical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0221064A external-priority patent/GB2392836B/en
Application filed by Johnson & Johnson Medical Limited filed Critical Johnson & Johnson Medical Limited
Priority to AU2003263332A priority Critical patent/AU2003263332A1/en
Publication of WO2004024196A1 publication Critical patent/WO2004024196A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments

Definitions

  • the present invention relates to wound dressing materials, and in particular to new materials for the controlled release of therapeutic agents into wounds.
  • Wound healing is a complex dynamic process that results in the restoration of anatomic continuity and function; an ideally healed wound is one that has returned to normal anatomic structure, function and appearance.
  • Chronically contaminated wounds all contain tissue bacterial flora. These bacteria may be indigenous to the patient or might be exogenous to the wound. Closure, or eventual healing of the wound is often based on a physician's ability to control the level of the bacterial flora.
  • antimicrobial wound dressings are known having a liquid permeable wound contacting layer, an intermediate absorbent layer and an outer, liquid-impervious backing layer, in which one or more of the layers contains an antimicrobial agent.
  • EP-A-0599589 describes layered wound dressings having a wound contacting layer of a macromolecular hydrocolloid, an absorbent layer, and a continuous, microporous sheet intermediate the wound contacting layer and the absorbent layer.
  • the absorbent layer contains a low molecular weight antimicrobial agent that can diffuse into the wound.
  • the hydrocolloid absorbs wound fluid to form a non-adherent and wound friendly gel for contacting the wound.
  • the hydrocolloid gel may also function as a slow release matrix for a therapeutic agent.
  • EP-A-0371736 describes wound dressings comprising a biopolymer wound contacting layer, which may be chitosan, and a polyurethane film laminated to the biopolymer.
  • the biopolymer layer may contain antibacterial agents.
  • the biopolymer wound contacting layer absorbs wound fluid to form a wound contacting gel layer.
  • a wound dressing that will selectively release antimicrobial agents and/or pain relieving agents into infected wounds but not into non-infected wounds, such release into infected wounds taking place preferably even prior to obvious clinical symptoms of infection.
  • a wound dressing would provide early intervention with suitable treatment (e.g. a topical antimicrobial treatment) before wound chronicity sets in.
  • GB-A-2381452 discloses that wound fluid from wounds that are apparently not clinically infected but which go on to become infected within a few days have high levels of neutrophil elastase activity and may also have high levels of other inflammatory enzymes, such as macrophage proteases, other neutrophil proteases, bacterial collagenase, plasmin, hyaluronidase, kallikrein or t-PA. It is also known that chronic wounds, such as venous ulcers, pressure sores and diabetic ulcers have a disordered wound healing metabolism even in the absence of infection. In particular, wound chronicity is associated with elevated levels of protease enzymes in the wound that interfere with the normal processes of tissue formation and destruction in the wound.
  • the present invention provides a wound dressing comprising: a therapeutic agent selected from the group consisting of antimicrobial substances, pain relieving substances, protease inhibitors, and mixtures thereof; and a barrier layer for initially separating the therapeutic agent from a wound fluid in use, wherein the barrier layer comprises a substrate for a host or bacterially derived chitinase or chitosanase enzyme.
  • the antimicrobial agent may, for example, comprise an antiseptic, an antibiotic, or mixtures thereof.
  • Preferred antibiotics include tetracycline, penicillins, terramycins, erythromycin, bacitracin, neomycin, polymycin B, mupirocin, clindamycin and mixtures thereof.
  • Preferred antiseptics include silver sulfadiazine, chlorhexidine, povidone iodine, triclosan, other silver salts, sucralfate, quaternary ammonium salts and mixtures thereof.
  • the pain relieving agent may be an analgesic or a local anaesthetic.
  • the chitinase or chitosanase enzyme is lysozyme.
  • Lysozyme is a naturally occurring antibacterial enzyme having a molecular weight of about 14.6 kD. It is found in most bodily secretions e.g. tears, mucosa and in the blood in larger amounts. Cellularly it is present in neutrophils and macrophages. In neutrophils it is present in their azurophil (or primary) granules contained in the cytoplasm.
  • Lysozyme hydrolyses the ⁇ 1-4 glycosidic linkage between N-acetyl-glucosamine (NAG) and N-acetylmuramic acid (NAM) in the bacterial cell wall.
  • NAG N-acetyl-glucosamine
  • NAM N-acetylmuramic acid
  • lysozyme is primarily active against Gram positive bacteria, which have no outer membrane to protect their cell wall. It has been found that infection is associated with elevated levels of lysozyme. Typical measured lysozyme levels are 8 ⁇ g/ml for uninfected serum and 192 ⁇ g/ml for infected wound fluid.
  • This invention uses the elevated levels of lysozyme in infected wound fluid relative to non-infected wound fluid as a trigger to release a suitable therapeutic agent from the dressing into the wound.
  • the barrier layer is separate from the therapeutic agent, and the therapeutic agent is initially prevented from contacting the wound fluid by the barrier layer. That is to say, the bioavailability of the therapeutic agent to the wound surface is low, and preferably substantially zero, until the barrier material has been broken down by lysozyme in the wound fluid, at which point the bioavailability increases sharply. Since the lysozyme levels are elevated in infected wounds, this provides for accelerated and/or selective release of the therapeutic agent into such wounds.
  • the barrier layer is normally substantially impervious to wound fluid and insoluble therein unless the wound fluid contains a sufficient level of the lysozyme to break down the substrate material.
  • the barrier layer preferably presents a solid barrier to the passage of wound fluid and therapeutic agents before it has been broken down by the specified enzymes.
  • the barrier layer is preferably not a gel-forming layer. That is to say, the barrier layer preferably does not absorb wound fluid to form a gel in use.
  • the barrier layer material preferably absorbs less than 0.5g/g of water following immersion at 30°C for 1 hour.
  • the barrier material may be any material that is broken down by a chitinase or chitosanase enzyme such as lysozyme.
  • the barrier material comprises a polysaccharide substrate for lysozyme, and preferably the polysaccharide comprises D-glucosamine or N-acetyl D-glucosamine residues.
  • the polysaccharide comprises chitin or chitosan.
  • Chitin is a natural biopolymer composed of N-acetyl-D-glucosamine units. Chitin may be extracted from the outer shell of shrimps and crabs in known fashion. The chitin is then partially deacetylated, for example by treatment with 5M-15M NaOH, to produce chitosan. Complete deacetylation of the chitin is not a practical possibility, but preferably the chitosan is at least 50% deacetylated, more preferably at least 75% deacetylated. Chitosan has been employed for wound treatment in various physical forms, e.g. as a solution/gel; film/membrane; sponge; powder or fiber.
  • Chitosan in the free base form is swellable but not substantially soluble in water at near-neutral pH, but soluble in acids due to the presence of ammonium groups on the chitosan chain.
  • the solubility of the chitosan may be reduced by cross-linking, for example with epichlorhydrin.
  • the solubility may also be modified by complexation with polyanions, such as sodium alginate.
  • the average molecular weight of the chitosan as determined by gel permeation chromatography is from about 10 5 to about 10 ⁇ .
  • the barrier layer is preferably about 0.1 to about 3 mm thick. Preferably about 0.5 to 1.5 mm thick.
  • the enzyme substrate material may be combined in a film- forming composition with additional polymeric materials, plasticisers, and humectants.
  • Suitable polymers include alginates, guar gum, carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, locust bean gum, carrageenan, heparan sulfate, dermatan sulfate, glycosaminoglycans such as hyaluronic acid, proteoglycans, and mixtures thereof.
  • Suitable plasticisers include C2-C8 polyhydric alcohols such as glycerol.
  • the enzyme substrate compounds make up at least about 10% by weight, more preferably at least about 20%, 30%, 40%, 50%, 60% or 75% by weight of the film-forming barrier composition.
  • the barrier layers of the dressings according to the present invention preferably are not broken down by protease enzymes present in wound fluid such as elastase, macrophage proteases, other neutrophil proteases, bacterial collagenase, plasmin, hyaluronidase, kallikrein or t-PA.
  • the barrier layer materials in the dressings according to the present invention comprise less than 25% by weight, preferably less than 10% by weight, of substrates for such protease enzymes such as gelatin, collagen or elastin.
  • the barrier layer comprises a substantially continuous film comprising the film forming composition of the enzyme substrate as described above.
  • these embodiments are not preferred because of the difficulty of making a sufficiently thin film that is sufficiently conformable and liquid-tight.
  • the barrier layer comprises an apertured sheet having a composition comprising the substrate material applied thereto in occlusive fashion.
  • the occlusive composition may be similar to the film-forming composition described above.
  • the term "apertured sheet” encompasses sheets having apertures larger than at least about 10 micrometers, whereby the sheets are permeable to liquid water.
  • the apertured sheet before application of the barrier material may be any medically acceptable, liquid-permeable woven, nonwoven or knitted textile sheet, or it may be a liquid-permeable foam or sponge sheet, or it may be an apertured thermoplastic film.
  • the apertures typically make up from about 0.1% to about 50% of the area of the wound facing surface of the sheet, more typically from about 1 % to about 30% of the area of the apertured sheet, and preferably from about 10% to about 25% of the area of the apertured sheet.
  • the apertured film has from about 1 to about 30 apertures per square cm, for example from about 4 to about 15 apertures per square cm or from about 5 to about 10 apertures per square cm.
  • the apertures are uniformly distributed over the surface of the sheet, preferably in a regular pattern.
  • each aperture may for example be from about 0.01 to about 10 mm 2 , preferably from about 0.1 to about 4 mm 2 , and more preferably from about 1 mm 2 to about 2mm 2 .
  • the sheet may include more than one size and shape of aperture in order to provide apertures that open more or less quickly on exposure to infected wound fluid. This enables still more control over the dynamics of therapeutic agent delivery to the wound.
  • the film may contain fewer, larger apertures or even only a single aperture. Typically, substantially the whole area of the apertures in the the apertured sheet is blocked by the barrier material before exposure to wound exudate.
  • the thickness of the barrier film or the apertured sheet (by ASTM D374- 79) is from about 0.2 to about 5 mm, more preferably from about 0.4 to about 3 mm.
  • the barrier layer material may further comprise a polymer selected from the group consisting of bioerodible polymers such as polylactide/polyglycolide, collagen, gelatin, polyacrylate gels such as those described in EP-A-0676457, calcium alginate gels, cross-linked hyaluronate gels, gels of alginate derivatives such as propylene glycol alginate, and gels wherein the hydropolymer is formed from vinyl alcohols, vinyl esters, vinyl ethers and carboxy vinyl monomers, meth(acrylic) acid, acrylamide, N-vinyl pyrrolidone, acylamidopropane sulphonic acid, PLURONIC (Registered Trade Mark) (block polyethylene glycol, block polypropylene glycol) polystyrene-, maleic acid, NN- dimethylacrylamide diacetone acrylamide, acryloyl morpholine, and mixtures thereof. Any of the above polymers may be cross-linked.
  • the barrier layer material may further comprise from about 5 to about 75% by weight, preferably from 15 to 40% by weight, on the same basis of one or more humectants such as glycerol.
  • the barrier layer material may further contain up to about 30% w/w, more preferably up to about 15% w/w on the same basis of water.
  • wound dressings have a layered structure wherein preferably a layer of the antimicrobial substance is provided behind the barrier layer. That is to say, on the side of the barrier layer opposite to the wound facing surface of the barrier layer in use.
  • the layer of antimicrobial substance may contact the barrier layer directly, or may be separated therefrom for example by an absorbent layer.
  • the barrier sheet according to these embodiments of the invention forms part of a layered wound dressing having the antimicrobial material disposed on the side of the barrier sheet opposite to the wound facing side of the barrier sheet.
  • the layered wound dressing further comprises an absorbent layer and/or a backing layer.
  • the area of the optional absorbent layer is typically in the range of from 1cm 2 to
  • the optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including gauzes, nonwoven fabrics, superabsorbents, hydrogels and mixtures thereof.
  • the absorbent layer comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A- 0541391, the entire content of which is expressly incorporated herein by reference.
  • the absorbent layer may be a nonwoven fibrous web, for example a carded web of viscose staple fibers.
  • the basis weight of the absorbent layer may be in the range of 50-500g/m 2 , such as 100-400g/m 2 .
  • the uncompressed thickness of the absorbent layer may be in the range of from 0.5mm to 10mm, such as 1mm to 4mm.
  • the free (uncompressed) liquid absorbency measured for physiological saline may be in the range of 5 to 30 g/g at 25°.
  • the antimicrobial material may be dispersed in or on the absorbent layer.
  • the dressing further comprises a backing layer covering the barrier sheet and the optional absorbent layer on the side opposite the wound-facing side of the dressing.
  • the backing layer preferably provides a barrier to passage of microorganisms through the dressing and further preferably blocks the escape of wound fluid from the dressing.
  • the backing layer may extend beyond at least one edge of the barrier sheet and optional absorbent layer to provide an adhesive- coated margin adjacent to the said edge for adhering the dressing to a surface, such as to the skin of a patient adjacent to the wound being treated.
  • An adhesive- coated margin may extend around all sides of the barrier sheet and optional absorbent layer, so that the dressing is a so-called island dressing. However, it is not necessary for there to be any adhesive-coated margin.
  • the backing layer is substantially liquid-impermeable.
  • the backing sheet is preferably semipermeable. That is to say, the backing sheet is preferably permeable to water vapour, but not permeable to liquid water or wound exudate.
  • the backing sheet is also microorganism-impermeable.
  • Suitable continuous conformable backing sheets will preferably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 5000 g/m 2 /24hrs, preferably 500 to 2000 g/m 2 /24hrs at 37.5 °C at 100% to 10% relative humidity difference.
  • the backing sheet thickness is preferably in the range of 10 to 1000 micrometers, more preferably 100 to 500 micrometers.
  • Suitable polymers for forming the backing sheet include polyurethanes and poly alkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A- 1280631.
  • the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell.
  • a suitable backing sheet material is the polyurethane film available under the Registered Trade Mark ESTANE 5714F.
  • the adhesive layer should be moisture vapor transmitting and/or patterned to allow passage of water vapor therethrough.
  • the adhesive layer is preferably a continuous moisture vapor transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings, for example, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane as described for example in GB-A-1280631.
  • the basis weight of the adhesive layer is preferably 20 to 250 g/m 2 , and more preferably 50 to 150 g/m 2 . Polyurethane-based pressure sensitive adhesives are preferred.
  • the adhesive layer extends outwardly from the absorbent layer and the envelope to form an adhesive-coated margin on the backing sheet around the absorbent layer as in a conventional island dressing.
  • the wound dressings according to the present invention may further comprise at least one wound facing layer for separating the barrier material from the wound surface in use.
  • the wound facing layer where present, is permeable to wound fluid.
  • the wound facing layer may be any medically acceptable wound facing sheet, including woven and nonwoven textile materials.
  • the wound facing sheet comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A-0541391 , the entire content of which is expressly incorporated herein by reference.
  • the wound facing layer comprises an apertured thermoplastic film.
  • Suitable thermoplastics include polyolefins such as polyethylene, copolymers such as ethylene methyl acrylate, or fluoropolymers such as polyvinylidene fluoride.
  • the wound facing layer comprises an apertured film of water-insoluble hydrogel material.
  • the apertured sheet may be a self-supporting sheet of such a hydrogel material as described in WO03/011352, the entire content of which are incorporated herein by reference.
  • the wound facing sheet may be coated on either, or both, surfaces with a layer of hydrogel, which may be apertured, to provide improved control of wound moisture levels and to provide a more wound-friendly dressing.
  • a layer of hydrogel which may be apertured, to provide improved control of wound moisture levels and to provide a more wound-friendly dressing.
  • Suitable hydrogel coatings are described in WO02/38097 and WO03/045294, the entire contents of which are incorporated herein by reference.
  • the barrier layer substantially encapsulates the antimicrobial substance.
  • the active substance may be dissolved or dispersed in the material making up the barrier layer sheet.
  • the dressing may comprise, or consist essentially of, particles such as microspheres of antimicrobial material encapsulated in a layer comprising the substrate material. The particles are preferably loaded with from 1 to 90 wt.%, more preferably from 3 to 50 wt.% of the antimicrobial agents.
  • the particles may be made by any suitable technique, including comminution, coacervation, or two-phase systems for example as described in US-A-3886084. Techniques for the preparation of medicated microspheres for drug delivery are reviewed, for example, in Polymeric Nanopartic.es and Microspheres, Guiot and Couvreur eds., CRC Press (1986).
  • a preferred method for preparation of the microparticles is coacervation, which is especially suited to the formation of particles in the preferred size range of 100 to 500 micrometers having a high loading of therapeutic agents.
  • Coacervation is the term applied to the ability of a number of aqueous solutions of colloids, to separate into two liquid layers, one rich in colloid solute and the other poor in colloid solute. Factors which influence this liquid-liquid phase separation are: (a) the colloid concentration, (b) the solvent of the system, (c) the temperature, (d) the addition of another polyelectrolyte, and (e) the addition of a simple electrolyte to the solution. Coacervation can be of two general types.
  • the first is called “simple” or “salt” coacervation where liquid phase separation occurs by the addition of a simple electrolyte to a colloidal solution.
  • the second is termed “complex” coacervation where phase separation occurs by the addition of a second colloidal species to a first colloidal solution, the particles of the two dispersed colloids being oppositely charged.
  • materials capable of exhibiting an electric charge in solution i.e. materials which possess an ionizable group are coacervable.
  • Such materials include natural and synthetic macromolecular species such as gelatin, acacia, tragacanth, styrene-maleic anhydride copolymers, methyl vinyl ether-maleic anhydride copolymers, polymethacrylic acid, and the like.
  • a water-immiscible material such as an oil
  • a simple electrolyte such as sodium sulfate, or another, oppositely charged colloidal species
  • the encapsulating colloidal material forms around each oil droplet, thus investing each of said droplets in a liquid coating of the coacervated colloid.
  • the liquid coatings which surround the oil droplets must thereafter be hardened by cross-linking to produce solid-walled microcapsules
  • the wound dressing according to any aspect of the present invention is sterile and packaged in a microorganism-impermeable container.
  • Figure 1 shows a perspective view of the lower (wound contacting) surface of a wound dressing according to the invention with the wound contacting sheet according to the invention partially cut away; and
  • Figure 2 shows a plan view of a portion of the wound contacting sheet according to the invention from the dressing of Fig. 1.
  • the wound dressing 1 is an island-type self-adhesive wound dressing comprising a backing layer 2 of microporous liquid-impermeable polyurethane foam, such as ESTANE 5714F (Registered Trade Mark).
  • the backing layer is permeable to water vapor, but impermeable to wound exudate and microorganisms.
  • the backing layer 2 is coated with a substantially continuous layer 3 of pressure- sensitive polyurethane adhesive.
  • An absorbent island 4 containing the antimicrobial is adhered to a central region of the adhesive-coated backing sheet 2.
  • the absorbent island 4 comprises an absorbent layer 5 of gauze having a basis weight of about 250g/m 2 and impregnated with silver sulfadiazine in an amount of about 25g/m 2 .
  • a wound contacting barrier sheet 6 extends over the absorbent layer 5 and is wrapped around the absorbent layer 5, and adhered to the backing layer 2 behind the absorbent layer 5 by the adhesive 3.
  • the wound contacting sheet 6 consists of a support layer 7 of a perforated polypropylene film with 12 perforations per cm 2 in which the apertures 8 are occluded by a lysozyme-degradable film composition prepared as follows.
  • the perforated polypropylene film with 12 perforations per cm 2 was placed on the surface of the chitosan dispersion.
  • the sheet having the dispersion in the apertures thereof was then partially dried and peeled from the tray.
  • the resulting sheet material had the apertures of the polypropylene film occluded by a thin film of the chitosan composition.
  • the sheet material was then immersed in a coagulation bath of aqueous NaOH at pH13 to swell and coagulate (neutralise) the chitosan, followed by washing in deionized water (pH7) and drying.
  • the wound facing surface of the dressing shown in Figure 1 is protected by two silicone-coated release papers 9,10.
  • the dressing is packaged in a microorganism-impermeable pouch (not shown), and sterilised using gamma radiation.
  • the dressing 1 is removed from the package, the release papers 9,10 are removed, and the dressing is adhered to the skin around the wound by the adhesive layer 3, with the wound contacting sheet in contact with the wound to provide a sterile and absorbent dressing.
  • the dissolution of the chitosan in the presence of elevated levels of lysozyme triggers the release of antimicrobial active agent from the absorbent layer into the wound in response to increased lysozyme production by infected or chronic wounds. This has the further benefit of allowing excess exudate to escape through the perforated sheet 7 into the absorbent layer 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention a trait à un pansement, qui comprend : un agent thérapeutique sélectionné parmi les substances antimicrobiennes, les substances analgésiques, les inhibiteurs de protéase, et des mélanges de ceux-ci ; et une couche barrière, destinée, en cours d'utilisation, à séparer initialement l'agent thérapeutique de l'exsudat de la plaie, la couche barrière comprenant un substrat pour un lysozyme. Ledit substrat contient de préférence un chitosane. La couche barrière se décompose en cas de plaies infectées ou chroniques, ce qui libère de manière sélective la substance thérapeutique dans de telles plaies.
PCT/GB2003/003886 2002-09-11 2003-09-10 Pansements destines au traitement des plaies infectees WO2004024196A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003263332A AU2003263332A1 (en) 2002-09-11 2003-09-10 Wound dressings for the treatment of wound infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0221064.9 2002-09-11
GB0221064A GB2392836B (en) 2002-09-11 2002-09-11 Wound dressings for the treatment of wound infection
US47212603P 2003-05-19 2003-05-19
US60/472,126 2003-05-19

Publications (1)

Publication Number Publication Date
WO2004024196A1 true WO2004024196A1 (fr) 2004-03-25

Family

ID=31995697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003886 WO2004024196A1 (fr) 2002-09-11 2003-09-10 Pansements destines au traitement des plaies infectees

Country Status (2)

Country Link
AU (1) AU2003263332A1 (fr)
WO (1) WO2004024196A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101213A1 (fr) 2008-02-15 2009-08-20 Westfaelische Wilhelms-Universitaet Muenster Chitinosanase
EP3000487A1 (fr) * 2007-02-19 2016-03-30 Marine Polymer Technologies, Inc. Compositions hémostatiques et régimes thérapeutiques
US9642871B2 (en) 2010-04-15 2017-05-09 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-N-acetylglucosamine nanofibers
CN107018991A (zh) * 2017-04-26 2017-08-08 江南大学 一种银‑溶菌酶纳米簇修饰的抗菌薄膜
US9970303B2 (en) 2014-05-13 2018-05-15 Entrotech, Inc. Erosion protection sleeve
US10765698B2 (en) 2011-04-15 2020-09-08 Marine Polymer Technologies, Inc. Treatment of disease with poly-N-acetylglucosamine nanofibers
WO2020207877A1 (fr) * 2019-04-12 2020-10-15 T.J.Smith And Nephew,Limited Matériaux destinés à être en contact avec une plaie auto-gélifiants à libération d'iode

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903268A (en) * 1968-02-12 1975-09-02 Lescarden Ltd Chitin and chitin derivatives for promoting wound healing
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
US4803078A (en) * 1987-06-16 1989-02-07 Japan Gore-Tex, Inc. Wound dressing
EP0371736A2 (fr) * 1988-11-29 1990-06-06 Mitsubishi Kasei Corporation Pansement pour blessures
EP0460774A2 (fr) * 1985-11-09 1991-12-11 Btg International Limited Pansement pour blessure
WO1994006484A1 (fr) * 1992-09-14 1994-03-31 Novasso Oy Pansement protecteur pour blessure
EP0599589A1 (fr) * 1992-11-23 1994-06-01 JOHNSON & JOHNSON MEDICAL, INC. Pansement
US5597581A (en) * 1993-07-09 1997-01-28 Karl W. An Haak Chitosan foil for wound sealing and process for its preparation
US5836970A (en) * 1996-08-02 1998-11-17 The Kendall Company Hemostatic wound dressing
WO2001024840A1 (fr) * 1999-10-07 2001-04-12 Coloplast A/S Dispositif de traitement des plaies
DE10135676A1 (de) * 2001-07-21 2003-02-06 Degussa Bioactives Deutschland Physiologisch verträglicher, Cellulose enthaltender Film

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903268A (en) * 1968-02-12 1975-09-02 Lescarden Ltd Chitin and chitin derivatives for promoting wound healing
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
EP0460774A2 (fr) * 1985-11-09 1991-12-11 Btg International Limited Pansement pour blessure
US4803078A (en) * 1987-06-16 1989-02-07 Japan Gore-Tex, Inc. Wound dressing
EP0371736A2 (fr) * 1988-11-29 1990-06-06 Mitsubishi Kasei Corporation Pansement pour blessures
WO1994006484A1 (fr) * 1992-09-14 1994-03-31 Novasso Oy Pansement protecteur pour blessure
EP0599589A1 (fr) * 1992-11-23 1994-06-01 JOHNSON & JOHNSON MEDICAL, INC. Pansement
US5597581A (en) * 1993-07-09 1997-01-28 Karl W. An Haak Chitosan foil for wound sealing and process for its preparation
US5836970A (en) * 1996-08-02 1998-11-17 The Kendall Company Hemostatic wound dressing
WO2001024840A1 (fr) * 1999-10-07 2001-04-12 Coloplast A/S Dispositif de traitement des plaies
DE10135676A1 (de) * 2001-07-21 2003-02-06 Degussa Bioactives Deutschland Physiologisch verträglicher, Cellulose enthaltender Film

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3000487A1 (fr) * 2007-02-19 2016-03-30 Marine Polymer Technologies, Inc. Compositions hémostatiques et régimes thérapeutiques
US10383971B2 (en) 2007-02-19 2019-08-20 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
WO2009101213A1 (fr) 2008-02-15 2009-08-20 Westfaelische Wilhelms-Universitaet Muenster Chitinosanase
US9642871B2 (en) 2010-04-15 2017-05-09 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-N-acetylglucosamine nanofibers
US10206938B2 (en) 2010-04-15 2019-02-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-N-acetylglucosamine nanofibers
US10561677B2 (en) 2010-04-15 2020-02-18 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-N-acetylglucosamine nanofibers
US10765698B2 (en) 2011-04-15 2020-09-08 Marine Polymer Technologies, Inc. Treatment of disease with poly-N-acetylglucosamine nanofibers
US9970303B2 (en) 2014-05-13 2018-05-15 Entrotech, Inc. Erosion protection sleeve
CN107018991A (zh) * 2017-04-26 2017-08-08 江南大学 一种银‑溶菌酶纳米簇修饰的抗菌薄膜
WO2020207877A1 (fr) * 2019-04-12 2020-10-15 T.J.Smith And Nephew,Limited Matériaux destinés à être en contact avec une plaie auto-gélifiants à libération d'iode

Also Published As

Publication number Publication date
AU2003263332A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
US7732655B2 (en) Controlled release therapeutic wound dressings
EP1429702B1 (fr) Pansements therapeutiques avec agrandissement d'ouvertures en fonction de l'exsudat
GB2392836A (en) Wound dressings for the treatment of wound infection
US7772454B2 (en) Wound treatment device
EP3672655B1 (fr) Biomatériau et procédés de fabrication et d'utilisation dudit biomatériau
Kurakula et al. Alginate-based hydrogel systems for drug releasing in wound healing
EP1341561B1 (fr) Pansement pour traitement de plaies suintantes
US8067370B2 (en) Pain-sensitive therapeutic wound dressing
EP1545637B1 (fr) Pansements therapeutiques sensibles aux enzymes
Agarwal et al. Polymeric materials for chronic wound and burn dressings
EP3500221B1 (fr) Pansement collagène/orc encapsulé dans une enveloppe biorésorbable
JP2004520096A (ja) ヒドロゲル創傷被覆材
JP2022523780A (ja) 抗菌ドレッシング、ドレッシング構成要素、及び方法
WO2004024196A1 (fr) Pansements destines au traitement des plaies infectees
GB2379392A (en) Wound dressing sheet materials
WO2004030712A1 (fr) Pansement therapeutique a liberation regulee
GB2393724A (en) Controlled release therapeutic wound dressings
GB2401041A (en) Pain-sensitive therapeutic wound dressings

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP